Roche (RHHBY) Reports FDA Grants Priority Review for Genentech's Perjeta for Adjuvant Treatment of HER2-Positive Early Breast Cancer
Tweet Send to a Friend
Genentech, a member of the Roche Group (OTC: RHHBY), today announced the U.S. Food and Drug Administration (FDA) has accepted ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
